Update shared on24 Oct 2025
Fair value Increased 3.22%Kiniksa Pharmaceuticals International’s analyst price target has increased from $48.86 to $50.43. Analysts cite strengthened commercial execution, robust product launches, and ongoing expansion opportunities as supporting factors for their upward revision.
Analyst Commentary
Analysts have weighed in on Kiniksa Pharmaceuticals International's recent performance and outlook, offering insight into both their optimism and potential areas of caution. Their commentary focuses on commercial progress, pipeline development, and growth sustainability.
Bullish Takeaways- Bullish analysts believe Kiniksa is at a pivotal stage in its growth, supported by the ongoing ramp of Arcalyst and the potential of new pipeline assets such as KPL-387.
- Recent price target increases reflect strong commercial execution and the company's ability to exceed expectations in quarterly results.
- There is confidence in Kiniksa's ability to deepen penetration within its existing target populations as well as the potential to expand to larger patient groups, which could significantly improve long-term earnings.
- Pipeline diversification and possibly more favorable dosing options may help extend the company's revenue franchise and create further value for shareholders.
- Bearish analysts note that rapid price target increases leave little margin for error in meeting ambitious commercial and clinical milestones.
- The commercial success of new products, particularly KPL-387, is not yet proven in larger or more competitive indications.
- There is some concern that expanding into larger patient populations could face unforeseen obstacles, both regulatory and market-related, which could delay growth trajectories.
What's in the News
- Kiniksa Pharmaceuticals International, plc raised its 2025 net product revenue guidance to between $625 million and $640 million, up from previous expectations of $590 million to $605 million (Company Guidance).
Valuation Changes
- Consensus Analyst Price Target has risen from $48.86 to $50.43. This reflects a modest upward revision in overall fair value estimates.
- Discount Rate has increased slightly from 7.17% to 7.21%. This indicates a marginally higher risk premium applied in the latest valuation models.
- Revenue Growth projection has moved up from 23.80% to 24.16%. This signals expectations for accelerated top-line expansion.
- Net Profit Margin is now forecast at 18.45%, up from 18.31%. This denotes incremental improvements in profitability.
- Future P/E Ratio estimate has edged higher to 26.59x from 26.16x. This suggests analysts anticipate sustained earnings growth supporting higher valuations.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.